Skip to main content
Top
Published in: Cancer Chemotherapy and Pharmacology 6/2014

01-12-2014 | Review Article

MicroRNAs: a new key in lung cancer

Authors: Yunlong Zhang, Qian Yang, Siwang Wang

Published in: Cancer Chemotherapy and Pharmacology | Issue 6/2014

Login to get access

Abstract

Lung cancer as a malignance has been killing numerous patients around the world annually, and small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC) are the two major types, the later accounting for nearly 80 % of lung cancer. There are multiple causes for lung cancer, and more researches have been carried out to prevent, anticipate, and diagnose the cancer. MicroRNAs (miRNAs) are small non-coding RNA molecules capable of regulating expression of over 50 % of protein-coding genes. The RNA molecules are stable in tissues and blood, so it can tend to be a biomarker in anti-lung cancer. Here, this is a review on the roles of miRNAs for possible ways to prevent lung cancer in clinical trials.
Literature
1.
go back to reference Pan X, Zhang X, Sun H, Zhang J, Yan M, Zhang H (2013) Autophagy inhibition promotes 5-fluorouraci-induced apoptosis by stimulating ROS formation in human non-small cell lung cancer A549 cells. PLoS One 8(2):e56679PubMedCentralPubMedCrossRef Pan X, Zhang X, Sun H, Zhang J, Yan M, Zhang H (2013) Autophagy inhibition promotes 5-fluorouraci-induced apoptosis by stimulating ROS formation in human non-small cell lung cancer A549 cells. PLoS One 8(2):e56679PubMedCentralPubMedCrossRef
2.
go back to reference Hsin IL, Ou CC, Wu TC, Jan MS, Wu MF, Chiu LY et al (2011) GMI, an immunomodulatory protein from Ganoderma microsporum, induces autophagy in non-small cell lung cancer cells. Autophagy 7(8):873–882PubMedCrossRef Hsin IL, Ou CC, Wu TC, Jan MS, Wu MF, Chiu LY et al (2011) GMI, an immunomodulatory protein from Ganoderma microsporum, induces autophagy in non-small cell lung cancer cells. Autophagy 7(8):873–882PubMedCrossRef
3.
go back to reference Liu J, Hu XJ, Jin B, Qu XJ, Hou KZ, Liu YP (2012) β-Elemene induces apoptosis as well as protective autophagy in human non-small-cell lung cancer A549 cells. J Pharm Pharmacol 64:146–153PubMedCrossRef Liu J, Hu XJ, Jin B, Qu XJ, Hou KZ, Liu YP (2012) β-Elemene induces apoptosis as well as protective autophagy in human non-small-cell lung cancer A549 cells. J Pharm Pharmacol 64:146–153PubMedCrossRef
4.
go back to reference Chen HS, Portier K, Ghosh K, Naishadham D, Kim HJ, Zhu L et al (2012) Predicting US and state-level cancer counts for the current calendar year: part I—evaluation of temporal projection methods for mortality. Cancer 118(4):1091–1099PubMedCentralPubMedCrossRef Chen HS, Portier K, Ghosh K, Naishadham D, Kim HJ, Zhu L et al (2012) Predicting US and state-level cancer counts for the current calendar year: part I—evaluation of temporal projection methods for mortality. Cancer 118(4):1091–1099PubMedCentralPubMedCrossRef
5.
go back to reference Saintigny P, Burger JA (2012) Recent advances in non-small cell lung cancer biology and clinical management. Discov Med 13:287–297PubMed Saintigny P, Burger JA (2012) Recent advances in non-small cell lung cancer biology and clinical management. Discov Med 13:287–297PubMed
6.
go back to reference Ajabnoor GM, Crook T, Coley HM (2012) Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells. Cell Death Dis 3:e260PubMedCentralPubMedCrossRef Ajabnoor GM, Crook T, Coley HM (2012) Paclitaxel resistance is associated with switch from apoptotic to autophagic cell death in MCF-7 breast cancer cells. Cell Death Dis 3:e260PubMedCentralPubMedCrossRef
7.
8.
go back to reference Hornstein E, Mansfield JH, Yekta S, Hu JK, Harfe BD et al (2005) The microRNA miR-196 acts upstream of Hoxb8 and Shh in limb development. Nature 438:671–674PubMedCrossRef Hornstein E, Mansfield JH, Yekta S, Hu JK, Harfe BD et al (2005) The microRNA miR-196 acts upstream of Hoxb8 and Shh in limb development. Nature 438:671–674PubMedCrossRef
13.
14.
go back to reference Esquela-Kerscher A, Slack FJ (2006) Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 6:259–269PubMedCrossRef Esquela-Kerscher A, Slack FJ (2006) Oncomirs—microRNAs with a role in cancer. Nat Rev Cancer 6:259–269PubMedCrossRef
15.
go back to reference Zhou M, Liu Z, Zhao Y, Ding Y, Liu H et al (2010) MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of proapoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 285:21496–21507PubMedCentralPubMedCrossRef Zhou M, Liu Z, Zhao Y, Ding Y, Liu H et al (2010) MicroRNA-125b confers the resistance of breast cancer cells to paclitaxel through suppression of proapoptotic Bcl-2 antagonist killer 1 (Bak1) expression. J Biol Chem 285:21496–21507PubMedCentralPubMedCrossRef
16.
go back to reference Fujita Y, Kojima K, Ohhashi R, Hamada N, Nozawa Y et al (2010) MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem 285:19076–19084PubMedCentralPubMedCrossRef Fujita Y, Kojima K, Ohhashi R, Hamada N, Nozawa Y et al (2010) MiR-148a attenuates paclitaxel resistance of hormone-refractory, drug-resistant prostate cancer PC3 cells by regulating MSK1 expression. J Biol Chem 285:19076–19084PubMedCentralPubMedCrossRef
17.
go back to reference Aora T, Liu B, He H (2003) PIASx is a transcriptional co-repressor of signal transducer and activator of transcription. J Biol Chem 278(24):21327–21330CrossRef Aora T, Liu B, He H (2003) PIASx is a transcriptional co-repressor of signal transducer and activator of transcription. J Biol Chem 278(24):21327–21330CrossRef
18.
go back to reference Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR (2005) MicroRNA expression profiles classify human cancers. Nature 435:834–838PubMedCrossRef Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA, Downing JR, Jacks T, Horvitz HR, Golub TR (2005) MicroRNA expression profiles classify human cancers. Nature 435:834–838PubMedCrossRef
19.
go back to reference Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102:13944–13949PubMedCentralPubMedCrossRef Cimmino A, Calin GA, Fabbri M, Iorio MV, Ferracin M, Shimizu M, Wojcik SE, Aqeilan RI, Zupo S, Dono M, Rassenti L, Alder H, Volinia S, Liu CG, Kipps TJ, Negrini M, Croce CM (2005) miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci USA 102:13944–13949PubMedCentralPubMedCrossRef
21.
go back to reference Leucci E, Zriwil A, Gregersen LH, Jensen KT, Obad S, Bellan C, Leoncini L, Kauppinen S, Lund AH (2012) Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo. Oncogene 31:5081–5089PubMedCrossRef Leucci E, Zriwil A, Gregersen LH, Jensen KT, Obad S, Bellan C, Leoncini L, Kauppinen S, Lund AH (2012) Inhibition of miR-9 de-represses HuR and DICER1 and impairs Hodgkin lymphoma tumour outgrowth in vivo. Oncogene 31:5081–5089PubMedCrossRef
22.
go back to reference Ling H, Fabbri M, Calin GA (2013) MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 12:847–865PubMedCrossRef Ling H, Fabbri M, Calin GA (2013) MicroRNAs and other non-coding RNAs as targets for anticancer drug development. Nat Rev Drug Discov 12:847–865PubMedCrossRef
23.
go back to reference Osada H, Takahashi T (2011) let-7 and miR-17-92: small-sized major players in lung cancer development. Cancer Sci 102:9–17PubMedCrossRef Osada H, Takahashi T (2011) let-7 and miR-17-92: small-sized major players in lung cancer development. Cancer Sci 102:9–17PubMedCrossRef
24.
go back to reference Ke Y, Zhao W, Xiong J, Cao R (2013) Downregulation of miR-16 promotes growth and motility by targeting HDGF in non-small cell lung cancer cells. FEBS Lett 587:3153–3157PubMedCrossRef Ke Y, Zhao W, Xiong J, Cao R (2013) Downregulation of miR-16 promotes growth and motility by targeting HDGF in non-small cell lung cancer cells. FEBS Lett 587:3153–3157PubMedCrossRef
25.
go back to reference Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P, Gasparini P, Gonelli A, Costinean S, Acunzo M, Condorelli G, Croce CM (2009) miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16:498–509PubMedCentralPubMedCrossRef Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, Taccioli C, Pichiorri F, Alder H, Secchiero P, Gasparini P, Gonelli A, Costinean S, Acunzo M, Condorelli G, Croce CM (2009) miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell 16:498–509PubMedCentralPubMedCrossRef
26.
go back to reference Chen G, Umelo IA, Lv S, Teugels E, Fostier K, Kronenberger P, Dewaele A, Sadones J, Geers C, De Greve J (2013) miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PLoS One 8:e60317PubMedCentralPubMedCrossRef Chen G, Umelo IA, Lv S, Teugels E, Fostier K, Kronenberger P, Dewaele A, Sadones J, Geers C, De Greve J (2013) miR-146a inhibits cell growth, cell migration and induces apoptosis in non-small cell lung cancer cells. PLoS One 8:e60317PubMedCentralPubMedCrossRef
27.
go back to reference Reck M, Von Pawel J, Zatloukal P et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancel: AVAil. J Clin Oncol 27:1227–1234PubMedCrossRef Reck M, Von Pawel J, Zatloukal P et al (2009) Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancel: AVAil. J Clin Oncol 27:1227–1234PubMedCrossRef
28.
go back to reference Seagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543–3551CrossRef Seagliotti GV, Parikh P, von Pawel J et al (2008) Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapynaive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 26:3543–3551CrossRef
29.
go back to reference Yanaihara N, Caplen N, Bowman E et al (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9:189–198PubMedCrossRef Yanaihara N, Caplen N, Bowman E et al (2006) Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell 9:189–198PubMedCrossRef
30.
go back to reference Lebanony D, Benjamin H, Gilad S et al (2009) Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from non-squamous non-small cell lung carcinoma. J Clin Oncol 27:2030–2037PubMedCrossRef Lebanony D, Benjamin H, Gilad S et al (2009) Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from non-squamous non-small cell lung carcinoma. J Clin Oncol 27:2030–2037PubMedCrossRef
31.
go back to reference Landi MT, Zhao Y, Rotunno M et al (2010) MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 16:430–441PubMedCentralPubMedCrossRef Landi MT, Zhao Y, Rotunno M et al (2010) MicroRNA expression differentiates histology and predicts survival of lung cancer. Clin Cancer Res 16:430–441PubMedCentralPubMedCrossRef
32.
go back to reference Del Vescovo V, Cantaloni C, Cucino A et al (2011) miR-205 Expression levels in non-small cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas. Am J Surg Pathol 35:268–275PubMedCrossRef Del Vescovo V, Cantaloni C, Cucino A et al (2011) miR-205 Expression levels in non-small cell lung cancer do not always distinguish adenocarcinomas from squamous cell carcinomas. Am J Surg Pathol 35:268–275PubMedCrossRef
33.
go back to reference Guan P, Yin Z, Li X et al (2012) Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues. J Exp Clin Cancer Res 31:54PubMedCentralPubMedCrossRef Guan P, Yin Z, Li X et al (2012) Meta-analysis of human lung cancer microRNA expression profiling studies comparing cancer tissues with normal tissues. J Exp Clin Cancer Res 31:54PubMedCentralPubMedCrossRef
34.
go back to reference Sun Y, Su B, Zhang P et al (2013) Expression of miR-150 and miR-3940-5p is reduced in non-small lung carcinoma and correlates with clinicopathological features. Oncol Rep 29:704–712PubMed Sun Y, Su B, Zhang P et al (2013) Expression of miR-150 and miR-3940-5p is reduced in non-small lung carcinoma and correlates with clinicopathological features. Oncol Rep 29:704–712PubMed
35.
go back to reference Zhu W, Liu X, He J et al (2011) Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study. BMC Cancer 11:393PubMedCentralPubMedCrossRef Zhu W, Liu X, He J et al (2011) Overexpression of members of the microRNA-183 family is a risk factor for lung cancer: a case control study. BMC Cancer 11:393PubMedCentralPubMedCrossRef
36.
go back to reference Chen X, Ba Y, Ma L et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18(10):997–1006PubMedCrossRef Chen X, Ba Y, Ma L et al (2008) Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res 18(10):997–1006PubMedCrossRef
37.
go back to reference Foss KM, Sima C, Ugolini D et al (2011) miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early stage non-small cell lung cancer. J Thorac Oncol 6(3):482–488PubMedCrossRef Foss KM, Sima C, Ugolini D et al (2011) miR-1254 and miR-574-5p: serum-based microRNA biomarkers for early stage non-small cell lung cancer. J Thorac Oncol 6(3):482–488PubMedCrossRef
39.
go back to reference Keller A, Leidinger P, Borries A et al (2009) miRNAs in lung cancer studying complex fingerprints in patients blood cells by microarray experiments. BMC Cancer 9:353PubMedCentralPubMedCrossRef Keller A, Leidinger P, Borries A et al (2009) miRNAs in lung cancer studying complex fingerprints in patients blood cells by microarray experiments. BMC Cancer 9:353PubMedCentralPubMedCrossRef
40.
go back to reference Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F, Muti P, Strano S, Blandino G (2012) MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 19:1038–1048PubMedCentralPubMedCrossRef Donzelli S, Fontemaggi G, Fazi F, Di Agostino S, Padula F, Biagioni F, Muti P, Strano S, Blandino G (2012) MicroRNA-128-2 targets the transcriptional repressor E2F5 enhancing mutant p53 gain of function. Cell Death Differ 19:1038–1048PubMedCentralPubMedCrossRef
41.
go back to reference Romano G, Acunzo M, Garofalo M, Di Leva G, Cascione L, Zanca C, Bolon B, Condorelli G, Croce CM (2012) MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. Proc Natl Acad Sci USA 109:16570–16575PubMedCentralPubMedCrossRef Romano G, Acunzo M, Garofalo M, Di Leva G, Cascione L, Zanca C, Bolon B, Condorelli G, Croce CM (2012) MiR-494 is regulated by ERK1/2 and modulates TRAIL-induced apoptosis in non-small-cell lung cancer through BIM down-regulation. Proc Natl Acad Sci USA 109:16570–16575PubMedCentralPubMedCrossRef
42.
go back to reference Melo SA, Esteller M (2011) Dysregulation of microRNAs in cancer: playing with fire. FEBS Lett 585:2087–2099PubMedCrossRef Melo SA, Esteller M (2011) Dysregulation of microRNAs in cancer: playing with fire. FEBS Lett 585:2087–2099PubMedCrossRef
43.
go back to reference Zandberga E, Kozirovskis V, Abols A, Andrejeva D, Purkalne G, Line A (2013) Cell-free microRNAs as diagnostic, prognostic, and predictive biomarkers for lung cancer. Genes Chromosomes Cancer 52:356–369PubMedCrossRef Zandberga E, Kozirovskis V, Abols A, Andrejeva D, Purkalne G, Line A (2013) Cell-free microRNAs as diagnostic, prognostic, and predictive biomarkers for lung cancer. Genes Chromosomes Cancer 52:356–369PubMedCrossRef
44.
go back to reference Barshack I, Lithwick-Yanai G, Afek A, Rosenblatt K, Tabibian-Keissar H, Zepe-niuk M, Cohen L, Dan H, Zion O, Strenov Y, Polak-Charcon S, Perelman M (2010) MicroRNA expression differentiates between primary lung tumors and metastases to the lung. Pathol Res Pract 206:578–584PubMedCrossRef Barshack I, Lithwick-Yanai G, Afek A, Rosenblatt K, Tabibian-Keissar H, Zepe-niuk M, Cohen L, Dan H, Zion O, Strenov Y, Polak-Charcon S, Perelman M (2010) MicroRNA expression differentiates between primary lung tumors and metastases to the lung. Pathol Res Pract 206:578–584PubMedCrossRef
45.
go back to reference Kaduthanam S, Gade S, Meister M, Brase JC, Johannes M, Dienemann H, Warth A, Schnabel PA, Herth FJ, Sultmann H, Muley T, Kuner R (2013) SerummiR-142-3p is associated with early relapse in operable lung adenocarcinoma patients. Lung Cancer 80:223–227PubMedCrossRef Kaduthanam S, Gade S, Meister M, Brase JC, Johannes M, Dienemann H, Warth A, Schnabel PA, Herth FJ, Sultmann H, Muley T, Kuner R (2013) SerummiR-142-3p is associated with early relapse in operable lung adenocarcinoma patients. Lung Cancer 80:223–227PubMedCrossRef
46.
go back to reference Ulivi P, Foschi G, Mengozzi M, Scarpi E, Silvestrini R, Amadori D, Zoli W (2013) Peripheral blood miR-328 expression as a potential biomarker for the early diagnosis of NSCLC. Int J Mol Sci 14:10332–10342PubMedCentralPubMedCrossRef Ulivi P, Foschi G, Mengozzi M, Scarpi E, Silvestrini R, Amadori D, Zoli W (2013) Peripheral blood miR-328 expression as a potential biomarker for the early diagnosis of NSCLC. Int J Mol Sci 14:10332–10342PubMedCentralPubMedCrossRef
47.
go back to reference Ranade AR, Cherba D, Sridhar S, Richardson P, Webb C, Paripati A, Bowles B, Weiss GJ (2010) MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer. J Thorac Oncol 5:1273–1278PubMedCrossRef Ranade AR, Cherba D, Sridhar S, Richardson P, Webb C, Paripati A, Bowles B, Weiss GJ (2010) MicroRNA 92a-2*: a biomarker predictive for chemoresistance and prognostic for survival in patients with small cell lung cancer. J Thorac Oncol 5:1273–1278PubMedCrossRef
48.
go back to reference Li ZH, Zhang H, Yang ZG, Wen GQ, Cui YB, Shao GG (2013) Prognostic significance of serum microRNA-210 levels in non-small-cell lung cancer. J Int Med Res 41:1437–1444PubMedCrossRef Li ZH, Zhang H, Yang ZG, Wen GQ, Cui YB, Shao GG (2013) Prognostic significance of serum microRNA-210 levels in non-small-cell lung cancer. J Int Med Res 41:1437–1444PubMedCrossRef
49.
go back to reference Wei J, Gao W, Zhu CJ, Liu YQ, Mei Z, Cheng T, Shu YQ (2011) Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer 30:407–414PubMedCentralPubMedCrossRef Wei J, Gao W, Zhu CJ, Liu YQ, Mei Z, Cheng T, Shu YQ (2011) Identification of plasma microRNA-21 as a biomarker for early detection and chemosensitivity of non-small cell lung cancer. Chin J Cancer 30:407–414PubMedCentralPubMedCrossRef
50.
go back to reference Franchina T, Amodeo V, Bronte G, Savio G, Ricciardi GR, Picciotto M, Russo A, Giordano A, Adamo V (2014) Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer. J Cell Physiol 229:97–99PubMed Franchina T, Amodeo V, Bronte G, Savio G, Ricciardi GR, Picciotto M, Russo A, Giordano A, Adamo V (2014) Circulating miR-22, miR-24 and miR-34a as novel predictive biomarkers to pemetrexed-based chemotherapy in advanced non-small cell lung cancer. J Cell Physiol 229:97–99PubMed
51.
go back to reference William WN Jr, Glisson BS (2011) Novel strategies for the treatment of small-cell lung carcinoma. Nat Rev Clin Oncol 8:611–619PubMedCrossRef William WN Jr, Glisson BS (2011) Novel strategies for the treatment of small-cell lung carcinoma. Nat Rev Clin Oncol 8:611–619PubMedCrossRef
52.
go back to reference Larsen JE, Cascone T, Gerber DE, Heymach JV, Minna JD (2011) Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J 17:512–527PubMedCentralPubMedCrossRef Larsen JE, Cascone T, Gerber DE, Heymach JV, Minna JD (2011) Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J 17:512–527PubMedCentralPubMedCrossRef
53.
go back to reference Wang XC, Du LQ, Tian LL, Wu HL, Jiang XY, Zhang H, Li DG, Wang YY, Wu HY, She Y, Liu QF, Fan FY, Meng AM (2011) Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer. Lung Cancer 72:92–99PubMedCrossRef Wang XC, Du LQ, Tian LL, Wu HL, Jiang XY, Zhang H, Li DG, Wang YY, Wu HY, She Y, Liu QF, Fan FY, Meng AM (2011) Expression and function of miRNA in postoperative radiotherapy sensitive and resistant patients of non-small cell lung cancer. Lung Cancer 72:92–99PubMedCrossRef
55.
go back to reference Lee KM, Choi EJ, Kim IA (2011) microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Radiother Oncol 101:171–176PubMedCrossRef Lee KM, Choi EJ, Kim IA (2011) microRNA-7 increases radiosensitivity of human cancer cells with activated EGFR-associated signaling. Radiother Oncol 101:171–176PubMedCrossRef
56.
go back to reference Chen S, Wang H, Ng WL, Curran WJ, Wang Y (2011) Radiosensitizing effects of ectopic miR-101 on non-small-cell lung cancer cells depend on the endogenous miR-101 level. Int J Radiat Oncol Biol Phys 81:1524–1529PubMedCrossRef Chen S, Wang H, Ng WL, Curran WJ, Wang Y (2011) Radiosensitizing effects of ectopic miR-101 on non-small-cell lung cancer cells depend on the endogenous miR-101 level. Int J Radiat Oncol Biol Phys 81:1524–1529PubMedCrossRef
57.
go back to reference Balca-Silva J, Sousa Neves S, Goncalves AC, Abrantes AM, Casalta-Lopes J, Botelho MF, Sarmento-Ribeiro AB, Silva HC (2012) Effect of miR-34b overexpression on the radiosensitivity of non-small cell lung cancer cell lines. Anticancer Res 32:1603–1609PubMed Balca-Silva J, Sousa Neves S, Goncalves AC, Abrantes AM, Casalta-Lopes J, Botelho MF, Sarmento-Ribeiro AB, Silva HC (2012) Effect of miR-34b overexpression on the radiosensitivity of non-small cell lung cancer cell lines. Anticancer Res 32:1603–1609PubMed
58.
go back to reference Liu ZL, Wang H, Liu J, Wang ZX (2013) MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol Cell Biochem 372:35–45PubMedCrossRef Liu ZL, Wang H, Liu J, Wang ZX (2013) MicroRNA-21 (miR-21) expression promotes growth, metastasis, and chemo- or radioresistance in non-small cell lung cancer cells by targeting PTEN. Mol Cell Biochem 372:35–45PubMedCrossRef
59.
go back to reference Salim H, Arvanitis A, de Petris L, Kanter L, Haag P, Zovko A, Ozata DM, Lui WO, Lundholm L, Zhivotovsky B, Lewensohn R, Viktorsson K (2013) miRNA-214 is related to invasiveness of human non-small cell lung cancer and directly regulates alpha protein kinase 2 expression. Genes Chromosomes Cancer 52:895–911PubMedCrossRef Salim H, Arvanitis A, de Petris L, Kanter L, Haag P, Zovko A, Ozata DM, Lui WO, Lundholm L, Zhivotovsky B, Lewensohn R, Viktorsson K (2013) miRNA-214 is related to invasiveness of human non-small cell lung cancer and directly regulates alpha protein kinase 2 expression. Genes Chromosomes Cancer 52:895–911PubMedCrossRef
60.
go back to reference Grosso S, Doyen J, Parks SK, Bertero T, Paye A, Cardinaud B, Gounon P, Lacas-Gervais S, Noel A, Pouyssegur J, Barbry P, Mazure NM, Mari B (2013) MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis 4:e544PubMedCentralPubMedCrossRef Grosso S, Doyen J, Parks SK, Bertero T, Paye A, Cardinaud B, Gounon P, Lacas-Gervais S, Noel A, Pouyssegur J, Barbry P, Mazure NM, Mari B (2013) MiR-210 promotes a hypoxic phenotype and increases radioresistance in human lung cancer cell lines. Cell Death Dis 4:e544PubMedCentralPubMedCrossRef
61.
go back to reference Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, Wang B, Suster S, Jacob ST, Ghoshal K (2008) Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem 283:33394–33405PubMedCentralPubMedCrossRef Nasser MW, Datta J, Nuovo G, Kutay H, Motiwala T, Majumder S, Wang B, Suster S, Jacob ST, Ghoshal K (2008) Down-regulation of micro-RNA-1 (miR-1) in lung cancer. Suppression of tumorigenic property of lung cancer cells and their sensitization to doxorubicin-induced apoptosis by miR-1. J Biol Chem 283:33394–33405PubMedCentralPubMedCrossRef
62.
go back to reference Wang Q, Zhong M, Liu W, Li J, Huang J, Zheng L (2011) Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 37:427–434PubMedCrossRef Wang Q, Zhong M, Liu W, Li J, Huang J, Zheng L (2011) Alterations of microRNAs in cisplatin-resistant human non-small cell lung cancer cells (A549/DDP). Exp Lung Res 37:427–434PubMedCrossRef
63.
go back to reference Feng B, Wang R, Chen LB (2012) MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett 317:184–191PubMedCrossRef Feng B, Wang R, Chen LB (2012) MiR-100 resensitizes docetaxel-resistant human lung adenocarcinoma cells (SPC-A1) to docetaxel by targeting Plk1. Cancer Lett 317:184–191PubMedCrossRef
64.
go back to reference Catuogno S, Cerchia L, Romano G, Pognonec P, Condorelli G, de Franciscis V (2013) miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene 32:341–351PubMedCrossRef Catuogno S, Cerchia L, Romano G, Pognonec P, Condorelli G, de Franciscis V (2013) miR-34c may protect lung cancer cells from paclitaxel-induced apoptosis. Oncogene 32:341–351PubMedCrossRef
65.
go back to reference Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, Servant N, Paccard C, Hupe P, Robert T, Ripoche H, Lazar V, Harel-Bellan A, Dessen P, Barillot E, Kroemer G (2010) miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 70:1793–1803PubMedCrossRef Galluzzi L, Morselli E, Vitale I, Kepp O, Senovilla L, Criollo A, Servant N, Paccard C, Hupe P, Robert T, Ripoche H, Lazar V, Harel-Bellan A, Dessen P, Barillot E, Kroemer G (2010) miR-181a and miR-630 regulate cisplatin-induced cancer cell death. Cancer Res 70:1793–1803PubMedCrossRef
66.
go back to reference Lei L, Huang Y, Gong W (2013) miR-205 promotes the growth, metastasis and chemoresistance of NSCLC cells by targeting PTEN. Oncol Rep 30:2897–2902PubMed Lei L, Huang Y, Gong W (2013) miR-205 promotes the growth, metastasis and chemoresistance of NSCLC cells by targeting PTEN. Oncol Rep 30:2897–2902PubMed
67.
go back to reference Dong Z, Zhong Z, Yang L, Wang S, Gong Z (2014) MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9. Cancer Lett 343:249–257PubMedCrossRef Dong Z, Zhong Z, Yang L, Wang S, Gong Z (2014) MicroRNA-31 inhibits cisplatin-induced apoptosis in non-small cell lung cancer cells by regulating the drug transporter ABCB9. Cancer Lett 343:249–257PubMedCrossRef
68.
go back to reference Huang JY, Cui SY, Chen YT, Song HZ, Huang GC, Feng B, Sun M, De W, Wang R, Chen LB (2013) MicroRNA-650 was a prognostic factor in human lung adenocarcinoma and confers the docetaxel chemoresistance of lung adenocarcinoma cells via regulating Bcl-2/Bax expression. PLoS One 8:e72615PubMedCentralPubMedCrossRef Huang JY, Cui SY, Chen YT, Song HZ, Huang GC, Feng B, Sun M, De W, Wang R, Chen LB (2013) MicroRNA-650 was a prognostic factor in human lung adenocarcinoma and confers the docetaxel chemoresistance of lung adenocarcinoma cells via regulating Bcl-2/Bax expression. PLoS One 8:e72615PubMedCentralPubMedCrossRef
69.
go back to reference Uchino K, Ochiya T, Takeshita F (2013) RNAi therapeutics and applications of microRNAs in cancer treatment. Jpn J Clin Oncol 43:596–607PubMedCrossRef Uchino K, Ochiya T, Takeshita F (2013) RNAi therapeutics and applications of microRNAs in cancer treatment. Jpn J Clin Oncol 43:596–607PubMedCrossRef
Metadata
Title
MicroRNAs: a new key in lung cancer
Authors
Yunlong Zhang
Qian Yang
Siwang Wang
Publication date
01-12-2014
Publisher
Springer Berlin Heidelberg
Published in
Cancer Chemotherapy and Pharmacology / Issue 6/2014
Print ISSN: 0344-5704
Electronic ISSN: 1432-0843
DOI
https://doi.org/10.1007/s00280-014-2559-9

Other articles of this Issue 6/2014

Cancer Chemotherapy and Pharmacology 6/2014 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine